Oramed Pharmaceuticals Inc.
ORMPHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. With a market capitalization of $208.4M, it sits in micro-cap territory. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
Market Cap
$208.4M
Beta
1.19
P/E (TTM)
1.21
P/E (Fwd)
-62.63
EPS (TTM)
$4.13
EPS (Fwd)
$-0.08
ROE
74.2%
ROA
-3.4%
Cash
$50.6M
Total Debt
$733,000
Free CF
$2.5M
52W Change
116.9%
Annual Financials
Cash vs Debt
Where ORMP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ORMP finished 28.68% above its 150-day moving average ($3.94) and 38.15% above its 200-day moving average ($3.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ORMP overbought or oversold?
At the September 3, 2026 close, ORMP's RSI(14) was 70.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Oramed Pharmaceuticals Inc. holds $50.6M in cash against $733K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $2.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 74.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $2.7M (2021) to $2.0M (2025), a 26% decline worth watching.
With cash comfortably exceeding debt, ORMP has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Oramed Pharmaceuticals Inc.'s trajectory.